Wall Street Zen Downgrades ADMA Biologics (NASDAQ:ADMA) to Hold

ADMA Biologics (NASDAQ:ADMA) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also commented on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Mizuho dropped their price objective on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $28.00.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $11.01 on Friday. The company’s fifty day moving average is $13.45 and its 200-day moving average is $15.81. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of 18.35 and a beta of 0.82. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same period last year, the business posted $0.46 earnings per share. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. Equities research analysts predict that ADMA Biologics will post 0.51 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms purchased 7,000 shares of the stock in a transaction on Thursday, March 5th. The shares were purchased at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Salomon & Ludwin LLC acquired a new stake in ADMA Biologics in the 3rd quarter valued at $25,000. Rothschild Investment LLC boosted its holdings in shares of ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,495 shares during the period. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics during the 4th quarter worth about $29,000. Clearstead Advisors LLC boosted its holdings in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter worth about $34,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.